Chief Medical Officer, Kailera Therapeutics
Scott Wasserman, MD, is Kailera’s Chief Medical Officer. Scott brings deep expertise in clinical development to Kailera, spanning global development strategy, clinical trial design and execution, and global regulatory interactions. Most recently, Scott served as Venture Partner at Frazier Life Sciences, focusing on company creation. Prior to Frazier, Scott was the CEO and co-founder of Latigo Biotherapeutics, a venture-backed biotechnology company developing first and best-in-class, non-opioid pain medicines.
Before Latigo, Scott was Vice President, Global Development Therapeutic Area Head for Bone, Cardiovascular, Metabolic, and Neuroscience at Amgen. He was Amgen’s first cardiologist and built the cardiovascular and metabolic portfolios and teams. Scott led the development and global approvals of Repatha® to reduce LDL-cholesterol and prevent heart attacks and strokes. He was instrumental in the development and FDA approval of Evenity® to treat osteoporosis in postmenopausal women at high fracture risk and also led the team in the FDA approval of Aimovig® for migraine prevention. Scott oversaw therapeutic development for a range of other conditions, including heart failure, anemia, obesity, and Alzheimer’s disease.
Prior to joining industry, Scott was on faculty at Stanford University in the Division of Cardiovascular Medicine conducting NIH-sponsored research on endothelial gene expression, and served as a non-interventional cardiologist at the Veterans Administration Hospital in Palo Alto, CA.
Scott received his BS, Magna Cum Laude from Haverford College and his MD, Magna Cum Laude from Harvard Medical School. He completed his postgraduate training in Internal Medicine and Cardiovascular Medicine at Stanford University and post-doctoral cardiovascular research at COR Therapeutics, Millennium Pharmaceuticals, and Stanford.